Canaccord Genuity Maintains Buy on GRAIL, Raises Price Target to $150

9/28/2026
Impact: 85
Healthcare

Canaccord Genuity analyst Kyle Mikson has maintained a Buy rating on GRAIL (NASDAQ: GRAL) and raised the price target from $80 to $150. This adjustment reflects a positive outlook for the company's performance.

AI summary, not financial advice

Share: